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inhibits protein translation. Although mammalian miR-
NAs were not discovered until a decade ago ( 2 ), they have 
rapidly emerged as important posttranscriptional regula-
tors of gene expression in a wide variety of biological path-
ways ( 3 ). Moreover, miRNAs have been demonstrated to 
be  i ) stable plasma biomarkers of physiological status ( 4, 
5 ),  ii ) novel intercellular signaling molecules ( 6 ),  iii ) etio-
logical factors in complex diseases ( 7 ), and  iv ) promising 
therapeutic targets ( 8, 9 ). 
 In 2002, miR-122 was found to be the most abundant 
miRNA in the liver, accounting for greater than 70% of all 
hepatic miRNA expression ( 2 ). More recent, high-through-
put small RNA sequencing (smRNA-seq) studies have 
confi rmed this fi nding and, notably, have not detected 
miR-122 in any other cell type ( 10 ). Circulating levels of 
miR-122 have been identifi ed as a clinically relevant bio-
marker of liver injury ( 11, 12 ), cirrhosis ( 13 ), necroinfl am-
mation ( 14 ), and hyperlipidemia ( 15 ). In 2005, miR-122 
was also shown to directly promote the replication of the 
hepatitis C virus (HCV) ( 16 ). Subsequently, it was demon-
strated that inhibition of miR-122 by a locked nucleic acid 
(LNA) antisense oligonucleotide diminishes HCV viremia 
in chimpanzees ( 17 ). The anti-miR-122 LNA molecule 
(known as Miravirsen) has since advanced to phase II 
human clinical trials for hepatitis C treatment, and it ap-
pears to induce a potent antiviral effect in the absence of 
evident liver or cardiac toxicities ( 18 ). 
 miR-122 was also the fi rst miRNA identifi ed as a regula-
tor of lipid metabolism ( 19 ). In 2006, antisense oligonu-
cleotide-mediated inhibition of miR-122 (ASO-miR-122) 
in mice reduced plasma cholesterol levels, decreased hepatic 
lipid synthesis, and enhanced hepatic fatty acid oxidation 
( 19 ). Moreover, the ASO-miR-122 was also able to reverse the 
effects of diet-induced obesity by reducing hepatic steatosis. 
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 HEPATIC MIRNAS AND LIPID HOMEOSTASIS 
 Non-coding RNA (ncRNA) is a diverse class of regula-
tory molecules involved in the control of gene expression 
( 1 ). Different subtypes of ncRNA mediate pre-, co-, and 
posttranscriptional regulatory processes. For instance, long 
noncoding RNA (lncRNA) facilitates chromatin remodeling, 
small nuclear RNA (snRNA) mediates splicing, and cyto-
plasmic microRNA (miRNA) destabilizes RNA and/or 
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affi nity for one or more TFs, and the resulting effect on 
transcription could directly infl uence lipid metabolic path-
ways. For example, several single nucleotide polymorphisms 
(SNP) in the core promoter region of the  low-density lipo-
protein receptor ( LDLR ) gene have been shown to abolish 
binding of the transcription factor Sp1 ( 49–53 ), which leads 
to familial hypercholesterolemia (FH). As another exam-
ple, a very recent study demonstrated that the minor allele 
of the SNP rs12740374, located within an LRE at the 1p13 
locus, dramatically increases the binding affi nity for the 
transcription factor CEBPA, which in turn alters the he-
patic expression of the gene  sortilin 1 ( SORT1 ), leading to 
impaired lipoprotein metabolism ( 54, 55 ). 
 Until recently, attempts to map disease-associated ge-
netic variants to miRNA transcriptional control elements 
have been severely hindered by poor annotation of miRNA 
promoters and LREs. Conventional methods for the iden-
tifi cation of a gene promoter, such as 5 ′ rapid amplifi cation 
of cDNA ends (5 ′ -RACE), require access to the full-length 
primary transcript of the gene. However, the primary tran-
scripts of miRNAs are often too rapidly processed and de-
graded, which renders these traditional approaches less 
reliable for miRNA promoter identifi cation ( 56 ). In the 
last few years, several conceptual and technological ad-
vances in the fi eld of epigenomics have allowed for the 
detection of miRNA promoter regions by analyzing chro-
matin structure ( 57, 58 ). Active promoters are characterized 
by a nucleosome-free site (open chromatin) that is fl anked 
by regions enriched for specifi c chromatin marks, includ-
ing histone H3 lysine 27 mono-acetylation (H3K27ac), his-
tone H3 lysine 4 tri-methylation (H3K4me3), and histone 
H3 lysine 79 di-methylation (H3K79me2). In the last few 
years, the application of epigenome-wide chromatin pro-
fi ling strategies has led to a comprehensive set of annota-
tions for mammalian miRNA promoters ( 42 ). 
 Largely due to the relatively recent annotation of miRNA 
promoters, disease-causing variants in miRNA transcrip-
tional control elements have not yet been extensively in-
vestigated. However, one illustrative example is that of a 
functional SNP (rs57095329) in the promoter of miR-146a 
that confers signifi cant risk for systemic lupus erythema-
tosus (SLE) ( 59 ). The rs57095329 minor allele reduces 
the binding affi nity for the transcriptional activator Ets1, 
which in turn reduces miR-146a expression ( 59 ). SLE is 
associated with dyslipoproteinemia ( 60, 61 ), including 
increased LDL oxidation (oxLDL) and atherosclerotic 
foam cell formation ( 60 ). Interestingly, miR-146a was re-
cently shown to inhibit oxLDL-induced lipid accumula-
tion by repressing toll-like receptor 4 (TLR4)-dependent 
signaling pathways in macrophages ( 62 ). Furthermore, 
viral administration of miR-146a to lupus-prone mice was 
found to inhibit the progression of SLE ( 63 ). Therefore, 
the overexpression of miR-146a may represent a novel 
preventative and/or therapeutic strategy for immune-re-
lated lipid disorders. 
 Genetic variation in miRNA target sites 
 Bona fi de miRNA target sites are distributed across the en-
tire transcriptome ( 64, 65 ) in noncoding RNAs, 5 ′ -untranslated 
Consistent with these fi ndings, Miravirsen (anti-miR-122 
LNA) has been shown to reduce plasma cholesterol levels 
in humans as well ( 18 ). Recently, miR-122 was also demon-
strated to be a critical regulator of hepatic circadian rhythm 
( 20 ), infl ammation ( 21 ), fi brosis ( 22 ), and lipoprotein se-
cretion ( 22 ); as such, it is a very important component of 
liver function and lipid homeostasis. 
 In the last few years, numerous studies have demon-
strated that physiological and pathological changes in 
lipid metabolism are associated with altered hepatic and 
circulating miRNA profi les ( 5, 15, 23–33 ). For example, 
Cheung et al. found that the expression levels of 46 hepatic 
miRNAs are signifi cantly altered in nonalcoholic steato-
hepatitis (NASH) compared with normolipidemic individu-
als ( 26 ). Moreover, they demonstrated that many miRNAs, 
including miR-145, miR-27b, miR-30d, and miR-34a, are 
more signifi cantly altered in NASH than miR-122. Very re-
cently, several of these miRNAs, such as miR-27b ( 28 ) and 
miR-34a ( 34 ), and a growing number of others, including 
miR-125a, miR-33, miR-370, miR-378, miR-613, and miR-
758, have been directly implicated in the regulation of 
lipid synthesis, transport, storage, and metabolism. Given 
these fi ndings, which have been summarized in several 
recent review articles ( 35–41 ), it is apparent that the activ-
ity of numerous miRNAs contributes to lipid homeostasis. 
 GENETIC VARIATION IN THE MIRNA REGULOME 
AND LIPID-RELATED DISORDERS 
 miRNA loci are transcribed predominantly by RNA 
Polymerase II ( 42 ), which yields primary transcripts (pri-
miRNA) that range from a few kilobases to a few hundred 
kilobases in length ( 43 ). Pri-miRNAs harbor one or more 
hairpin-like secondary structures, termed precursor miRNAs 
(pre-miRNA), which are cleaved and shuttled to the cyto-
plasm, where they are processed further into   22 bp 
double-stranded RNA duplexes ( 44 ). One of the strands, 
referred to as the mature miRNA, is loaded onto the RNA-
induced silencing complex (RISC). The miRNA guides 
and tethers the RISC to specifi c target sites within RNA 
molecules in order to regulate their stability and/or trans-
lation ( 3 ). The canonical pathway for miRNA biogenesis 
and targeting is shown in  Fig. 1 .  The miRNA regulome is 
defi ned as the compendium of regulatory elements that 
either regulate miRNA expression (transcriptional control 
elements and pre-miRNAs) or are regulated by miRNA ac-
tivity (RNA target sites). Genetic variation in the miRNA 
regulome can perturb miRNA expression and/or function, 
potentially contributing to a wide variety of lipid-related 
phenotypes ( 45–47 ). 
 Genetic variation in miRNA transcriptional 
control elements 
 Transcriptional control elements can be classifi ed as ei-
ther proximal (i.e., promoter) or distal (i.e., long-range 
regulatory elements; LRE). Both classes of elements recruit 
transcriptional factor (TF) complexes that enhance or si-
lence the expression of one or more genes ( 48 ). Genetic 
mutations within these elements can alter the binding 
1170 Journal of Lipid Research Volume 54, 2013
( PPARA ) ( 77 ). PPARA is a lipid-activated TF that regulates 
the expression of many genes involved in hepatic lipid me-
tabolism ( 78 ). Although the authors did not explicitly discuss 
the possibility of a miRNA-related mechanistic link, a simple 
search of the TargetScan database (http://targetscan.org) 
suggests that rs3892755 is located within a predicted tar-
get site for miR-1204. Also, because association does not 
imply causation, it is entirely possible that one or both of 
rs6008259 and rs3892755 tags a haplotype block that con-
tains the true functional variant(s). Therefore, in these 
types of cases, more detailed genetic and molecular ex-
periments are necessary to determine whether the mecha-
nism underlying the observed association is related to 
miRNA targeting. 
 In more recent candidate gene association studies of 
lipid-related phenotypes, miRNA-mediated mechanistic 
links have been explicitly tested. For instance, in 2011, 
Richardson et al. identifi ed a signifi cant association be-
tween a SNP (rs8887) in the 3 ′ -UTR of  perilipin 4 ( PLIN4 ) 
and adiposity in two cohorts composed of several thousand 
Caucasian individuals ( 70 ). They further demonstrated that 
the rs8887 minor allele is associated with reduced levels of 
 PLIN4 expression in adipose. Through an in silico target 
prediction strategy, they found that the rs8887 minor al-
lele creates a putative target site for an adipose-expressed 
miRNA, miR-522. They then provided experimental sup-
port for this prediction by establishing with in vitro reporter 
regions (UTR), open reading frames (ORF), and 3 ′ -UTRs. 
The 3 ′ -UTR sites are thought to be the most prevalent and 
functionally effi cacious ( 3 ). Numerous algorithms have 
been developed for large-scale miRNA target prediction 
within 3 ′ -UTRs ( 66 ). One of the most widely used in silico 
methods is TargetScan, which predicts target sites for a 
miRNA by searching for   7 nucleotide segments that 
perfectly complement the “seed” region (nucleotides 2 
through 8 at the 5 ′ -end) of the miRNA ( 67 ). Predicted 
“seed-match” sites are then scored according to fi ve other 
sequence features that have been shown to contribute to 
target site effi cacy ( 68 ). Genetic variation in predicted 
miRNA target sites has been demonstrated to have wide-
spread effects on miRNA-mediated gene regulation ( 69 ). 
Although the contribution of allele-specifi c miRNA target-
ing to lipid phenotypic variation in the human population 
is not yet fully understood, recent fi ndings summarized 
below strongly suggest that it is an area with substantive 
implications for the pharmacogenetics of lipid disorders. 
 Numerous candidate gene association studies have iden-
tifi ed SNPs within annotated 3 ′ -UTRs that may be associ-
ated with lipid-related phenotypes ( 70–77 ). One interesting 
2008 study of plasma cholesterol levels in   10,000 Cauca-
sians and   3,500 African Americans found signifi cant 
population-specifi c interaction effects between dietary 
fatty acid intake and two SNPs (rs6008259 and rs3892755) 
in the 3 ′ -UTR of  peroxisome proliferator-activated receptor   
 Fig.  1. microRNA biogenesis and targeting. The canonical pathway for miRNA maturation and targeting activity is shown. Red arrows 
indicate components of the miRNA regulome:  1 ) transcriptional control elements within miRNA promoter regions,  2 ) miRNA precursors 
(pre-miRNAs), and  3 ) miRNA target sites that are located predominantly within 3 ′ UTRs. Both pri-miRNAs and mRNAs are generally 
5 ′ -capped and polyadenylated. XPO5, exportin 5; NPC, nuclear pore complex. 
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( 88 ). One of these is the SNP rs3846662, which is strongly 
associated with the LCL expression levels of miR-221 ( P = 
1.1 × 10   7 ) and miR-222 ( P = 3.5 × 10   8 ), and also signifi -
cantly associated with total plasma cholesterol ( P = 3.0 × 
10   19 ). In support of this result, another recent study 
found that miR-221 and miR-222 are among the most sig-
nifi cantly downregulated hepatic miRNAs in baboons with 
high LDL-C that were fed a high-cholesterol/high-fat diet 
( 27 ). These interesting fi ndings highlight the utility of 
systems genetics approaches to generate miRNA-related 
mechanistic hypotheses for genetic loci associated with 
lipid-related traits/disorders. Moreover, the power to de-
tect miR-eQTLs associated with disease will only increase 
as studies such as the one by Gamazon et al. are performed 
in larger cohorts across broader sets of cell types.  
 The author thanks Jeanette Baran-Gale and Dr. Kasey Vickers 
for their helpful suggestions regarding the manuscript. 
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gene assays that miR-522 targets the  PLIN4 3 ′ -UTR only in 
the presence of the rs8887 minor allele. Taking their fi nd-
ings together, the authors proposed that differential 
miR-522 targeting activity underlies the genetic associa-
tion of the  PLIN4 locus with adiposity ( 70 ). It remains un-
clear why the reduction of PLIN4, which is thought to be 
involved in the biogenesis of lipid droplets, would lead to 
increased adiposity ( 79 ). Nonetheless, the authors’ inter-
esting fi ndings strongly motivate further investigation into 
the function of PLIN4 and other closely related protein 
family members. 
 None of the aforementioned genetic associations, which 
were based on candidate gene studies, have yet been con-
fi rmed by unbiased genome-wide association studies (GWAS). 
In the past few years, GWAS have been conducted for hun-
dreds of complex diseases and traits ( 80 ). Several bioinfor-
matic strategies have been developed to map GWAS-derived 
disease-associated variants, as well as SNPs in strong link-
age disequilibrium (LD), onto predicted miRNA target 
sites ( 81–86 ). A very recent approach uncovered 87 such 
SNPs ( 84 ). To date, only one of these, rs13702, has been 
validated by follow-up genetic and molecular studies ( 87 ). 
Specifi cally, Richardson et al. performed a large-scale 
genetic association study in more than 25,000 individu-
als from the Cohorts for Heart and Aging Research in 
Genomic Epidemiology (CHARGE) and confi rmed pre-
vious reports that the  lipoprotein lipase ( LPL ) 3 ′ UTR SNP 
rs13702 is associated with plasma lipid levels ( 87 ). They 
also demonstrated that this association is signifi cantly 
modulated by dietary intake of poly-unsaturated fatty 
acids (PUFA), providing evidence for gene-by-diet inter-
action. To identify the molecular basis for the observed 
genetic association/interaction, they fi rst performed an 
in silico screen for miRNA target sites and predicted an 
allele-specifi c target site for a widely expressed miRNA, 
miR-410. They then determined, via in vitro reporter 
gene assays, that miR-410 targets only the rs13702 major 
allele and that the rs13702 minor allele abrogates miR-410
-mediated repression of  LPL ( 87 ). This seminal study rep-
resents the best evidence to date for a miRNA-mediated 
mechanism underlying a GWAS-derived complex trait 
genetic association. 
 SYSTEMS GENETICS ANALYSIS OF MIRNA 
EXPRESSION: IMPLICATIONS FOR LIPID-RELATED 
TRAITS 
 Recently, Gamazon et al. carried out a large-scale study 
to identify genetic loci associated with miRNA expression 
(miRNA expression quantitative trait loci; miR-eQTL) in 
the lymphoblastoid cell lines (LCL) from 53 individuals of 
European ancestry (HapMap CEU) and 54 individuals of 
African ancestry (HapMap YRI) ( 88 ). They found that in 
the CEU and YRI samples, 1,792 and 1,390 SNPs, respectively, 
were modestly associated ( P < 10   6 ) with the expression lev-
els of 131 and 154 miRNAs, respectively. Furthermore, 
they reported that 21 of these miR-eQTLs were previously 
associated with several complex traits/diseases in GWAS 
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